{"brief_title": "A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection", "brief_summary": "To evaluate the clinical toxicity, safety, and MTD of WF 10 ( TCDO ) intravenous solution administered to patients with HIV infection. To evaluate the potential anti-HIV activity of TCDO.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "WF10", "criteria": "Inclusion Criteria Concurrent Medication: Required: - Aerosolized pentamidine (300 mg monthly) as prophylaxis for PCP only in patients with CD4 count <= 200 cells/mm3. Allowed: - PCP prophylaxis with aerosolized pentamidine in patients with CD4 count > 200 cells/mm3, only at the discretion of the treating physician. Patients must have: - HIV positivity. - Absolute CD4 count of 150 - 500 cells/mm3. - At least 6 months of prior zidovudine therapy. - No active opportunistic infection requiring ongoing therapy. - Life expectancy of at least 6 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Neoplasm other than basal cell carcinoma of the skin. - Clinically significant cardiac disease. - Abnormal neurological status by a standardized assessment including strength, reflex testing, and sensory testing. - Unwilling to comply with protocol requirements. Patients with the following prior conditions are excluded: History of myocardial infarction or arrhythmias. Prior Medication: Excluded within 2 weeks prior to study entry: - Antiretroviral agent or interferon. - Systemic biologic response modifiers, corticosteroids, cytotoxic chemotherapeutic agents, or other drugs that can cause neutropenia or significant nephrotoxicity. - Rifampin or rifampin derivatives. - Systemic anti-infectives. Required: - At least 6 months of prior zidovudine. Active drug or alcohol abuse.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002119.xml"}